Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
To establish that at least 1 dose of daclatasvir combined with standard of care (pegylated
interferon and ribavirin) is safe and well tolerated and demonstrates extended rapid
virologic response rates at least 35% greater than those with placebo.